Clinical trials: Cardiac Toxicity
Radiation Treatment, Cancer
Cardiac Effects From Radiation Therapy by MRI
The investigators will identify 10 patients in the department of radiation oncology who will receive standard of-care radiation therapy, and the treating radiation oncologist anticipates a mean left ventricular dose of at least 5…
- Conditions
- Radiation Treatment, Cancer, Cardiotoxicity
- Trial name
- NCT04486573
- Testing
- Cardiac Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Colorado, Denver
Neoplasms
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy
The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry…
- Trial name
- HARMONIC-RT (NCT04746729)
- Testing
- No intervention
- Where
- 5 sites in Belgium, Denmark and 2 more
- Volunteers
- 2,670 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Cardiotoxicity., Anti Her2 Therapy.
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes
Approximately 15-25% of all breast cancers are human epidermal growth factor receptor 2 (HER2) positive and it has been well known that HER2 overexpression is associated with more aggressive phenotype and poor prognosis with…
- Conditions
- Cardiotoxicity., Anti Her2 Therapy., Metastatic Breast Cancer
- Trial name
- NCT02101879
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rambam Health Care Campus
Cancer
Prevention of Anthracycline-induced Cardiotoxicity
Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi) and betablockers (BB) during the first…
- Trial name
- ICOS-ONE (NCT01968200)
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 268 people
- Sponsor
- European Institute of Oncology
Heart Failure, Breast Cancer
Cardiac Toxicity in Medical Treatment of Breast Cancer
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.
- Trial name
- CaTOB (NCT02440620)
- Where
- Denmark
- Volunteers
- 45 people
- Sponsor
- Odense University Hospital
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Breast Neoplasms
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
- Trial name
- ATOPE (NCT03787966)
- Testing
- ATOPE-B, ATOPE-I
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad de Granada
Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and…
- Conditions
- Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity, Anthracyclines
- Trial name
- MUSCLE (NCT05731375)
- Testing
- 31-MRS at 7 Tesla (T)
- Where
- 4 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
Cancer, Heart Failure
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To…
- Conditions
- Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy
- Trial name
- NCT06092606
- Testing
- Trial group: DH001 low-dose group, Trial group: DH001 high-dose group
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Monyan Pharmaceutical (Shanghai) Co., Ltd.
Neoplasms, Heart; Disease, Functional
Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study
As the numbers of cancer survivors grow, the long-term adverse effects of cancer therapy are becoming increasingly apparent. Most prominent are the toxic effects on the heart (cardiotoxicity) which may lead to cardiac dysfunction…
- Conditions
- Neoplasms, Heart; Disease, Functional, Inflammation
- Trial name
- EXACT (NCT02471053)
- Testing
- Moderate Intensity Exercise
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Nova Scotia Health Authority
Cardiotoxicity
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines* (decline of LVEF ≥10% points…
- Trial name
- CARDIOTOX (NCT04790266)
- Testing
- Cardiac MRI
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- Oncology Institute of Southern Switzerland
Breast Cancer
Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Trial name
- NCT06491680
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Helwan University
Non Hodgkin Lymphoma, DLBCL
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and…
- Conditions
- Non Hodgkin Lymphoma, DLBCL, Cardiovascular Diseases, Cardiomyopathies
- Trial name
- CLARITY (NCT07041827)
- Testing
- Cardiovascular assessment
- Where
- Netherlands
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
HIV Infections
Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children
This study will use the NIH-sponsored Women and Infants Transmission Study (WITS) and the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) HIV-infected pediatric cohorts to…
- Trial name
- NCT00260806
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 71 people
- Sponsor
- University of Miami
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors.
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Trial name
- NICBREASTRCT (NCT07897409)
- Testing
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Universiti Sains Malaysia
Non-small Cell Lung Cancer, Radiation Toxicity
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent…
- Trial name
- RICT-LUNG (NCT03416972)
- Testing
- Standard platinum-based chemoradiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non Small Cell Lung Cancer, Nephropathy
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Lung cancer is the leading cause of death worldwide, with non-small-cell lung cancer (NSCLC) being the most common histotype according to the global cancer observatory 2022.
- Conditions
- Non Small Cell Lung Cancer, Nephropathy, Cardiotoxicity
- Trial name
- NCT05746598
- Testing
- Cisplatin injection
- Where
- Egypt
- Volunteers
- 178 people
- Sponsor
- Ain Shams University
Neuroendocrine Tumors, Heart Failure
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG
The goal of this proposal is to produce and test high specific activity Ultratrace iobenguane I 123 in normal human volunteers.
- Trial name
- mIBG (NCT01730417)
- Testing
- no carrier added metaiodobenzylguanidine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bennett Chin